Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

This study is testing whether a combination of the chemotherapy drugs cetuximab and irinotecan can help patients with metastatic colorectal cancer (cancer that has spread) who originally had a RAS mutation but whose cancer has now converted to "NeoRAS wild-type" — meaning the mutation is no longer detectable — after earlier rounds of treatment. **You may be eligible if...** - You are 18 or older with confirmed colorectal cancer that has spread - Your cancer originally had a RAS mutation but now tests negative for RAS mutation (NeoRAS wild-type) based on liquid biopsy - You have already received two prior lines of standard treatment (including fluorouracil, oxaliplatin, and irinotecan-based therapies) - Your overall health is adequate for further chemotherapy **You may NOT be eligible if...** - Your cancer still has a detectable RAS mutation - You have a BRAF mutation in your tumor - You have not received prior standard chemotherapy regimens - You have severe organ dysfunction or other conditions that prevent chemotherapy Talk to your doctor to see if this trial is right for you.